James A R Nicoll

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. ncbi The biochemical aftermath of anti-amyloid immunotherapy
    Chera L Maarouf
    The Longtine Center for Neurodegenerative Biochemistry, Banner Sun Health Research Institute, Sun City, AZ, USA
    Mol Neurodegener 5:39. 2010
  2. ncbi Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
    Hannah A D Keage
    Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    BMC Neurol 9:3. 2009
  3. ncbi Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
    Elina Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK
    Alzheimers Res Ther 2:1. 2010
  4. ncbi Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome
    James A R Nicoll
    Clinical Neurosciences, Level E, Mailpoint 813, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
    Neuroreport 14:1923-6. 2003
  5. ncbi Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement
    James A R Nicoll
    Clinical Neurosciences, University of Southampton, Southampton General Hospital, Mailpoint 813, Southampton, SO 16 6YD, UK
    Neurobiol Aging 25:589-97; discussion 603-4. 2004
  6. ncbi A new role for astrocytes: beta-amyloid homeostasis and degradation
    James A R Nicoll
    Clinical Neurosciences, University of Southampton, Mailpoint 813, Southampton General Hospital, Southampton SO16 6YD, UK
    Trends Mol Med 9:281-2. 2003
  7. ncbi Association between APOE genotype, neuropathology and dementia in the older population of England and Wales
    J A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Neuropathol Appl Neurobiol 37:285-94. 2011
  8. ncbi Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report
    James A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Nat Med 9:448-52. 2003
  9. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
  10. ncbi Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease
    Delphine Boche
    Southampton General Hospital, University of Southampton, UK
    Acta Neuropathol 120:13-20. 2010

Collaborators

Detail Information

Publications32

  1. ncbi The biochemical aftermath of anti-amyloid immunotherapy
    Chera L Maarouf
    The Longtine Center for Neurodegenerative Biochemistry, Banner Sun Health Research Institute, Sun City, AZ, USA
    Mol Neurodegener 5:39. 2010
    ..These patients were compared to 6 non-immunized AD cases and 5 non-demented control (NDC) cases...
  2. ncbi Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
    Hannah A D Keage
    Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    BMC Neurol 9:3. 2009
    ..We searched the literature for prospective population-based epidemiological clinicopathological studies, free of the biases of other sampling techniques, which were used as a comparison...
  3. ncbi Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
    Elina Zotova
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK
    Alzheimers Res Ther 2:1. 2010
    ....
  4. ncbi Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome
    James A R Nicoll
    Clinical Neurosciences, Level E, Mailpoint 813, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
    Neuroreport 14:1923-6. 2003
    ....
  5. ncbi Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement
    James A R Nicoll
    Clinical Neurosciences, University of Southampton, Southampton General Hospital, Mailpoint 813, Southampton, SO 16 6YD, UK
    Neurobiol Aging 25:589-97; discussion 603-4. 2004
    ..Increased concentration of soluble Abeta leads to the formation of insoluble Abeta plaques, other features of AD pathology, and dementia...
  6. ncbi A new role for astrocytes: beta-amyloid homeostasis and degradation
    James A R Nicoll
    Clinical Neurosciences, University of Southampton, Mailpoint 813, Southampton General Hospital, Southampton SO16 6YD, UK
    Trends Mol Med 9:281-2. 2003
  7. ncbi Association between APOE genotype, neuropathology and dementia in the older population of England and Wales
    J A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Neuropathol Appl Neurobiol 37:285-94. 2011
    ..The prospective Medical Research Council Cognitive Function and Ageing Study neuropathology cohort is population-based sample in which donations are unbiased by dementia status...
  8. ncbi Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report
    James A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Nat Med 9:448-52. 2003
    ..The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9)...
  9. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
    ..Abeta immunotherapy can clear all Abeta species from the cortex. However, if it is to be used for treatment of established Alzheimer disease, then the residual tau pathology and cerebral amyloid angiopathy require further study...
  10. ncbi Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease
    Delphine Boche
    Southampton General Hospital, University of Southampton, UK
    Acta Neuropathol 120:13-20. 2010
    ..However, the continuing progression of cognitive decline in AD patients after Abeta immunisation may be explained by its lack of apparent effect on tangles...
  11. ncbi Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy
    Roy O Weller
    Clinical Neurosciences, University of Southampton School of Medicine, LD74, South Laboratory and Pathology Block, Southampton General Hospital, Southampton SO166YD, UK
    Acta Neuropathol 118:87-102. 2009
    ..Drainage of Abeta along perivascular pathways in ageing artery walls may need to be improved to maximise the potential for improvement of cognitive function with immunotherapy...
  12. ncbi Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis
    Delphine Boche
    Division of Clinical Neurosciences, School of Medicine, Southampton General Hospital, University of Southampton, Southampton SO16 6YD, UK
    Acta Neuropathol 120:369-84. 2010
    ..The information obtained will be important in helping to understand the pathogenesis not only of AD but also of other neurodegenerative disorders associated with protein aggregation...
  13. ncbi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
    ..Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes...
  14. ncbi Immunotherapy for Alzheimer's disease and other dementias
    Delphine Boche
    Division of Clinical Neurosciences, University of Southampton, School of Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK
    Curr Opin Neurol 18:720-5. 2005
    ..The aim of this article is to review the role of immunotherapy in the removal of proteins which accumulate abnormally in neurodegenerative disorders associated with dementia, in particular amyloid-beta accumulation in Alzheimer's disease...
  15. ncbi The role of the immune system in clearance of Abeta from the brain
    Delphine Boche
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Brain Pathol 18:267-78. 2008
    ..In animal models, immunotherapy at an early age can protect against Abeta accumulation and it will be interesting to see if this can usefully be applied to humans to prevent AD...
  16. ncbi Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease
    Roy O Weller
    Neuropathology, Division of Clinical Neurosciences, University of Southampton School of Medicine, Mail Point 813, Southampton SO16 6YD, United Kingdom
    Ann N Y Acad Sci 977:162-8. 2002
    ..Therapies to increase elimination of Abeta in AD need to consider the effects of CVD on the elimination of Abeta from the aging human brain...
  17. ncbi Pathophysiology of dementias and implications for therapy
    O Weller Roy
    Clinical Neurosciences, Mailpoint 813, Southampton General Hospital, Southampton, SO16 6YD, UK
    Indian J Pathol Microbiol 48:289-99. 2005
    ..Reducing cerebrovascular disease and facilitating elimination of Abeta along perivascular drainage routes may offer long-term preventative measuresfor both Vascular Dementia and for Alzheimer's disease...
  18. ncbi Microglia in neurodegenerative disease
    V Hugh Perry
    School of Biological Sciences, University of Southampton, Building 62, Boldrewood Campus, Southampton SO16 7PX, UK
    Nat Rev Neurol 6:193-201. 2010
    ..The fact that diseases with a chronic systemic inflammatory component are risk factors for Alzheimer disease implies that crosstalk occurs between systemic inflammation and microglia in the CNS...
  19. ncbi New neuropathological findings in Unverricht-Lundborg disease: neuronal intranuclear and cytoplasmic inclusions
    Nicola R Cohen
    Cellular Pathology, Southampton General Hospital, Southampton, UK
    Acta Neuropathol 121:421-7. 2011
    ..It also reveals a genetically defined neurodegenerative disease with both FUS and TDP-43 related pathology...
  20. ncbi Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele
    Cheryl A Hawkes
    Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
    PLoS ONE 7:e41636. 2012
    ..This effect may be mediated, in part, by changes in age-related expression of basement membrane proteins in the cerebral vasculature...
  21. ncbi Genetic influences on outcome following acute neurological insults
    Ryan J Waters
    Division of Clinical Neuroscience, University of Southampton, UK
    Curr Opin Crit Care 11:105-10. 2005
    ..To examine the evidence for a genetic influence on clinical outcome after a variety of acute neurologic events...
  22. ncbi Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease
    Mitchell K P Lai
    Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
    Neurobiol Dis 22:555-61. 2006
    ..This study suggests that APOE epsilon4 selectively affects presynaptic cholinergic function which may contribute to the clinical and neuropathological features of AD...
  23. ncbi APOE and cerebral amyloid angiopathy in the elderly
    Seth Love
    Department of Neuropathology, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
    Neuroreport 14:1535-6. 2003
    ..028). Possession of epsilon4 does not by itself confer an increased risk of CAA but may be associated with reduced longevity even in the absence of AD or cerebral haemorrhage...
  24. ncbi Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease
    Doris Culpan
    Department of Care of the Elderly, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, UK
    Neurosci Lett 350:61-5. 2003
    ..014, Fisher's exact test) suggesting that the 2-1-2 haplotype may be protective against AD...
  25. ncbi Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury
    Andrew D Kay
    Department of Neurosurgery, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    J Neurotrauma 20:943-52. 2003
    ..67, p = 0.01) between injury severity and the decrease in Abeta(1-40) concentration after TBI. In vivo, changes in apoE and Abeta concentration occur after TBI and may be important in the response of the human brain to injury...
  26. ncbi Apolipoprotein E polymorphism and neuropsychological outcome following subarachnoid haemorrhage
    Paul Graham Morris
    Department of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
    Acta Neurol Scand 109:205-9. 2004
    ..To investigate the association between APOE genotype and cognitive and emotional outcome following spontaneous subarachnoid haemorrhage (SAH)...
  27. ncbi Cerebral amyloid angiopathy: both viper and maggot in the brain
    Roy O Weller
    Ann Neurol 58:348-50. 2005
  28. ncbi Effect of apolipoprotein E genotype on hematoma volume after trauma
    Imran Liaquat
    Department of Neurosurgery, University of Glasgow, United Kingdom
    J Neurosurg 96:90-6. 2002
    ..CONCLUSIONS: Larger hematomas were found in head-injured patients with one or more APOE-epsilon4 alleles than in patients without the allele. This may contribute to the poorer outcomes observed in these patients...
  29. ncbi Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury
    Andrew D Kay
    Department of Neurosurgery, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    J Neurotrauma 20:717-23. 2003
    ..Treatment strategies targeting CNS lipid transport, required for neuronal sprouting and synaptogenesis, may be applicable to traumatic brain injury...
  30. ncbi Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage
    Mark O McCarron
    Department of Neurology, Altnagelvin Hospital, Londonderry, BT47 6SB, UK
    Lancet Neurol 3:484-92. 2004
    ....
  31. ncbi Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury
    Andrew D Kay
    Department of Neurosurgery, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    J Neurotrauma 20:243-50. 2003
    ..0001). We speculate that apoE is retained within the parenchyma of the central nervous system in response to injury where in view of previous data, it may have a protective role...
  32. ncbi Nucleus basalis of Meynert pathology in the human brain after fatal head injury
    Iain Murdoch
    The Wellcome Surgical Institute, University of Glasgow, United Kingdom
    J Neurotrauma 19:279-84. 2002
    ..This damage may contribute to persisting dysfunction of memory and cognition in head-injured patients who survive...